Simulations Plus, Inc. (SLP)
Simulations Plus (SLP) Reports Next Week: Wall Street Expects Earnings Growth
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Simulations Plus (SLP) Have the Potential to Rally 25.61% as Wall Street Analysts Expect?
The mean of analysts' price targets for Simulations Plus (SLP) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Bottom Fishing Club - Simulations Plus: Huge Potential In AI Drug Discovery
Simulations Plus appears to be a unique Buy candidate, driven by an ultra-low valuation and the potential for AI-inspired growth in drug discovery modeling. The FDA Modernization Act 2.0 and industry shift away from animal testing position SLP's software and consulting for long-term relevance. Despite late 2025's expected sales growth hiccup and margin pressure, SLP's strong balance sheet and historical undervaluation offer significant upside for contrarian investors.
Simulations Plus, Inc. (SLP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Simulations Plus, Inc. (NASDAQ:SLP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants Shawn O'Connor - Chief Executive Officer Presentation Unknown Analyst Well, thank you, everybody, for being here today. I'm delighted to introduce Shawn O'Connor, who's the CEO of Simulations Plus.
SLP's Q3 Earnings Top, Sales Up Y/Y, Stock Gains Despite Lowered View
Simulation Plus' fiscal Q3 2025 earnings surge 67% on Pro-ficiency gains, but a cut in 2025 outlook shows hurdles in biosimulation and services.
Simulations Plus, Inc. (SLP) Q3 2025 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2025 Earnings Conference Call July 14, 2025 5:00 PM ET Company Participants Shawn M. O'Connor - Chief Executive Officer William Frederick - EVP & CFO Conference Call Participants Christine Rains - William Blair & Company L.L.C.
Simulations Plus (SLP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simulations Plus: Further Downside Is Likely (Rating Downgrade)
Simulations Plus' Q3 FY25 results missed expectations, with revenue guidance cut sharply due to biopharma market weakness and services segment volatility. Organic growth continues to decelerate and the company's margins are under pressure. This situation is likely to persist, while the demand environment is soft. Simulations Plus' revenue multiple remains high, given its dependence on services and reliance on M&A to drive growth. As a result, further downside appears likely.
SLP Cuts FY25 Revenue Outlook, Begins Strategic Reorganization
Simulations Plus lowers FY25 revenue forecast and restructures operations as biotech headwinds hit services demand.
SLP Advances Predictive Toxicology With DILIsym 11: Shares to Benefit?
Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety.
Simulations Plus: Benefiting From FDA Modernization And AI
Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation.
Simulations Plus: I See Promising Growth, But I'm Staying Neutral
Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and promising pipeline expansions, operational inefficiencies and rising costs raise concerns about near-term profitability. Management's ability to convert backlog into profitable revenue and stabilize margins is crucial for long-term shareholder value.
